Dexamethasone Implant Improves Outcomes in Anti-VEGF Refractory DME, Study Finds

Results from the real-world AUSSIEDEX study suggest dexamethasone implant significantly improved anatomic outcomes at 52 weeks and showed no new safety concerns.

Related Keywords

Westmead ,New South Wales ,Australia ,Sydney ,Australian ,Paul Mitchell ,University Of Sydney ,Clinical Ophthalmology Eye Health ,Westmead Clinical School ,Professor Paul ,Professor Paul Mitchell ,Clinical Ophthalmology ,Eye Health ,